Method of treating skin inflammation
View Patent ↗Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
1. A method of treating skin inflammation comprising administering to a human subject exhibiting skin inflammation a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that specifically binds to antagonist of at least two cytokines selected from the group consisting of IL-17, IL-19, and IL-23, thereby treating the skin inflammation.
2. The method of claim 1 , wherein the skin inflammation is cutaneous inflammation.
3. The method of claim 1 , wherein the cutaneous inflammation is psoriasis.
4. The method of claim 1 , wherein the subject expresses an average value of at least 5 fold higher IL-17 expression in a non-lesional psoriatic skin sample compared to a normal skin sample, as quantified by real-time PCR.
5. The method of claim 1 , wherein the subject expresses an average value of at least 20 fold higher IL-19 expression in a non-lesional psoriatic skin sample compared to a normal skin sample as quantified by real-time PCR.
6. The method of claim 1 , wherein the antibody, or antigen-binding fragment thereof, specifically binds to IL-17 and IL-19.
7. The method of claim 6 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-19 is a monoclonal antibody or antigen-binding fragment thereof.
8. The method of claim 6 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-19 is a humanized antibody or antigen-binding fragment thereof.
9. The method of claim 6 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-19 is a bispecific antibody or antigen-binding fragment thereof.
10. The method of claim 1 , wherein the antibody, or antigen-binding fragment thereof, specifically binds to IL-17 and IL-23.
11. The method of claim 10 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-23 is a monoclonal antibody or antigen-binding fragment thereof.
12. The method of claim 11 , wherein the antibody, or antigen-binding fragment thereof, is a monoclonal antibody.
13. The method of claim 10 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-23 is a humanized antibody or antigen-binding fragment thereof.
14. The method of claim 13 , wherein the antibody, or antigen-binding fragment thereof, is a humanized antibody.
15. The method of claim 10 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-17 and IL-23 is a bispecific antibody or antigen-binding fragment thereof.
16. The method of claim 15 , wherein the antibody, or antigen-binding fragment thereof, is a bispecific antibody.
17. The method of claim 1 , wherein the antibody, or antigen-binding fragment thereof, specifically binds to IL-19 and IL-23.
18. The method of claim 17 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-19 and IL-23 is a monoclonal antibody or antigen-binding fragment thereof.
19. The method of claim 17 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-19 and IL-23 is a humanized antibody or antigen-binding fragment thereof.
20. The method of claim 17 , wherein the antibody, or antigen-binding fragment thereof, that specifically binds to IL-19 and IL-23 is a bispecific antibody or antigen-binding fragment thereof.